论文部分内容阅读
癫的治疗主要是药物控制发作 ,合理、科学地应用抗癫药物 (AEDs) ,70 %~ 80 %癫患者的发作可以得到控制。然而 ,还有 2 0 %~ 2 5 %的患者仍不得不忍受发作不能控制的痛苦和药物不良反应的双重折磨 ,部分患者变成了难治性癫。坚持AEDs的应用原则 ,是控制癫发作的关键。目前 ,临床上最有效的第一线AEDs有 6种 :苯妥英钠、苯巴比妥钠、卡马西平、丙戊酸钠、扑米酮及乙琥胺。近年来 ,新的AEDs不断发展 ,已用于临床有效的新的药物 :氨己烯酸、托吡酯、拉莫三嗪、加巴喷丁、奥卡西平、非氨酯等。这些新一代AEDs主要用于治疗婴儿痉挛、Lennox Gastaut综合征、肌阵挛性癫以及复杂部分性癫发作等难治性癫。
The treatment of epilepsy mainly drug-controlled attacks, rational, scientific use of anti-epileptic drugs (AEDs), 70% to 80% of epileptic patients can be controlled. However, there are still 20% ~ 25% of patients still have to endure uncontrollable pain and adverse drug reactions double torture, some patients have become refractory epilepsy. Adhere to the principle of the application of AEDs, is the key to control epileptic seizures. Currently, the most clinically effective first-line AEDs are six: phenytoin sodium, phenobarbital sodium, carbamazepine, sodium valproate, primidone and ethosuximide. In recent years, the new AEDs continue to evolve and have been used clinically effective new drugs: amino acid, topiramate, lamotrigine, gabapentin, oxcarbazepine, non-urethane and so on. These next-generation AEDs are primarily used to treat refractory epilepsy such as infantile spasms, Lennox Gastaut syndrome, myoclonic epilepsy and complex partial epileptic seizures.